Vivos Therapeutics (VVOS) EBT Margin (2020 - 2025)
Historic EBT Margin for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to 79.61%.
- Vivos Therapeutics' EBT Margin fell 118400.0% to 79.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.1%, marking a year-over-year decrease of 126200.0%. This contributed to the annual value of 74.47% for FY2024, which is 242600.0% up from last year.
- Latest data reveals that Vivos Therapeutics reported EBT Margin of 79.61% as of Q3 2025, which was down 118400.0% from 131.23% recorded in Q2 2025.
- In the past 5 years, Vivos Therapeutics' EBT Margin registered a high of 44.15% during Q1 2023, and its lowest value of 168.68% during Q4 2021.
- Over the past 5 years, Vivos Therapeutics' median EBT Margin value was 119.95% (recorded in 2021), while the average stood at 111.47%.
- In the last 5 years, Vivos Therapeutics' EBT Margin surged by 1152200bps in 2024 and then tumbled by -836200bps in 2025.
- Over the past 5 years, Vivos Therapeutics' EBT Margin (Quarter) stood at 168.68% in 2021, then increased by 9bps to 154.15% in 2022, then increased by 14bps to 132.45% in 2023, then surged by 41bps to 78.02% in 2024, then fell by -2bps to 79.61% in 2025.
- Its EBT Margin was 79.61% in Q3 2025, compared to 131.23% in Q2 2025 and 128.12% in Q1 2025.